Research has led to greater understanding of the disease, potential for better treatment options
ACR Advances Legislation to Increase Patients’ Access to Biologic Drugs to Treat Rheumatoid Arthritis and Other Conditions
The Patients’ Access to Treatments Act of 2013 would prevent insurance companies from tacking on an additional cost-sharing fee for the specialty medications
ACR/ARHP Annual Meeting 2012: Risk of Immunosuppression from Rheumatic Disease Therapies Poses Challenge for Rheumatologists
Therapies can raise patients’ risk of contracting tuberculosis or other infectious diseases, complicating treatment
ACR/ARHP Annual Meeting 2012: Physicians Find Treatment Options Limited for Scleroderma Bowel Disease
With few proven medical treatments for scleroderma bowel disease, physicians often recommend a lifestyle change for patients as a first treatment option
What Mick Jagger Can Teach Us About Growing Old Gracefully
Preventive lifestyle behaviors, including regular exercise, can compress morbidity and disability to the very end of our lives, say rheumatologists
ACR/ARHP Annual Meeting 2012: Understanding Pain Signals May Pave Path to More Effective Therapies
The ability to differentiate the types of pain affiliated with rheumatic diseases can help rheumatologists better diagnose and treat patients
ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
Novel strategies for treating osteoarthritis aim to relieve pain, rebuild or replenish deteriorated cartilage and bone, or to replace the joint through surgery
ACR/ARHP Annual Meeting 2012: Will Novel Strategies Lead to Breakthroughs in Treating Osteoarthritis?
Letter: Praise for SAPHO Syndrome Article
After reading your article on SAPHO, I may get a better treatment plan for my patient; thanks for drawing the attention of American College of Rheumatology members to an obscure condition that can vex patients and clinicians
ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
Rituximab established as the drug of choice in patients with severe disease relapse, though cyclophosphamide may still play an important role for some patients, say rheumatologists
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 41
- Next Page »